Natarajan Muthusamy is an associate professor in medicine division of hematology of Ohio state university.

B cell Leukemia and lymphoma, Lymphocyte growth and development, B cells and autoimmunity

Ramón Cacabelos is Professor and Chairman at the EuroEspes Chair of Biotechnology and Genomics Camilo José Cela University Madrid Spain and President of the EuroEspes Biomedical Research Center Institute for CNS Disorders Corunna Spain He earned his MD at Oviedo University Medical School Oviedo Spain and his PhD at Osaka University Medical School Osaka Japan where he has been working for almost a decade at the Department of Psychiatry He has published more than 400 peerreviewed papers and 17 books He has been teaching in 4 different universities in Spain and abroad for 20 years He serves as President of the Spanish Society of Genomic Medicine and is the current FounderPresident of the World Association of Genomic Medicine He served as a reviewer in more than 20 peerreviewed journals in the areas of neuroscience psychopharmacology drug development genomics and pharmacogenomics He organized several International Conferences over the past 10 years He is the EditorinChief of The EuroEspes Journal GenT; Genomic Medicine Pharmacogenomics and Health Biotechnology He received several national and international Awards

Basic and Clinical Neuroscience, Drug Development, Psychopharmacology, Neurogenetics, Genomics, Pharmacogenomics, Genomic Medicine

Francesco Marotta has completed his MD degree in 1981 and Specialized in Gastroenterology Endoscopy in 1986 with highest marks Fellow in gastroenterology at University of Chicago in 1982 Clinical Research Registrar in gastroenterology at the GIT Dept Groote Schuur Hospital University of CapeTown South Africa Selected by bilateral Ministries of Health for a japanesespoken PhD course in Japan at the Dept of Surgery Hirosaki University completed in 1990 Granted a Fellowship by the Japanese Ministry of Science at the National Cancer Center Tokyo Molecular biology stage at WelcomeBeecham Labs of London UK in 1993 and at GoodGene Lab in Korea in 2006 Research Professor at Dept of Nutrition Food Science Texas University USA Visiting professor for gastroenterology oxidative stress aging and nutragenomics at major asian universities For 10 years had directed a research center in Japan and cooperates with Nobel Prize Prof Luc Montagnier Editor and board member of several medical journals Has received several international prizes the last being the Genomic Pioneer Award 2009 Has coedited a successful book on agingintervention “Il Manifesto della Lunga Vita” “the manifesto of long life” Cofounder of the research group ReGenera which is working on an innovative model of preventive/regenerative medicine Has published about 100 papers and presented almost 400 communications

Gastroenterology & Endoscopy

Dr. Beata LeckaCzernik did her MS Biology 1980 Warsaw University Warsaw Poland.She did her PhD in Genetics Institute of Biochemistry and Biophysics Polish Academy of Sciences Warsaw Poland and her Postdoctoral Fellow in University of Arkansas for Medical Sciences Little Rock Arkansas.

Diabetes, obesity, and osteoporosis are major public health concerns due to their prevalence in our increasingly sedentary and aging society. The peroxisome proliferator-activated receptor-gamma (PPARg) transcription factor is a protein that regulates glucose metabolism and energy expenditure. This protein also regulates lineage commitment of bone marrow mesenchymal stem cells (MSC). PPARg protein is a target for a class of anti-diabetic drugs TZDs, which decrease glucose levels and increase insulin sensitivity. Although their beneficial anti-diabetic profile, prolonged treatment with these drugs leads to the bone loss and increased number of bone fractures in diabetic patients. Dr. Lecka-Czerniks research has demonstrated that TZDs affect bone mass by changing lineage commitment of MSC toward formation of fat cells (adipocytes) and away from formation of bone forming cells (osteoblast). As a result, TZD administration to animals, as well as to humans, leads to the bone loss and the gain of fat in the bone marrow. Her research also demonstrated that the similar mechanism involving PPARg protein is responsible for bone loss with aging.

Robert M Snapka is a Professor in the Departments of Radiology Medical Biochemistry and Molecular Virology Immunology and Medical Genetics at The Ohio State University Columbus Ohio 43210 USA. He earned his PhD at the University of California. He has over fifty peer reviewed publications and was the editor of the SV40 Replicon Model for Analysis of Anticancer Drugs Academic Press and RG Landes Co 1996 San Diego. He has teaching experience of more than 25 years including graduate courses in radiation biology cancer biology cell cycle regulation DNA replication and virology. He has served as a reviewer for peer reviewed articles in virology molecular biology, radiation biology, drug discovery, cancer biology, cell biology, photobiology and DNA repair. He has coorganized conferences on topoisomerases cancer new anticancer agents topoisomerases in cancer. He has been an invited platform speaker at national and international meetings.

Anticancer drug discovery and elucidation of drug mechanisms, with emphasis in the areas of topoisomerase targeting drugs and photoactive drugs. Postranslational modifications resulting from topoisomerase poisoning. Biomarkers of oxidative damage resulting from inflammation and disease.
Use of SV40 as a model mammalian replicon in studies of drugs and xenobiotics.

Ariel Fernandez is the Karl F. Hasselmann Chaired Professor of Bioengineering at Rice University, USA. He earned his Ph. D. from Yale University in 1984 fasted awarded Ph. D. at Yale. He has published over 300 peerreviewed papers, several book chapters and is the author of a book on rational drug design “Transformative Concepts for Drug Design: Target Wrapping”, Springer, 2010. He has accrued a teaching experience spanning almost 30 years, served as reviewer to all major journals in molecular biophysics and to NIH special panel on centers of excellence in systems biology. Amongst his various accolades he received the Camille and Henry Dreyfus TeacherScholar Award, the Alexander von Humboldt Award and the John Simon Guggenheim Foundation Fellowship. He is an honorary member of Collegium Basilea Switzerland and editor of Frontiers in Bioscience, Encyclopedia of Bioscience, Journal of Biological Physics and Chemistry Basel, Switzerland, etc.

Molecular basis of drug specificity, Transformative concepts in drug design, Nonadaptive origin of interactome complexity, Translational medicine, Molecular Theranostic Engineering, Protein folding as a many-body problem.

Dr. Jason P. Holland is an ETH Fellow in the Department of Radiopharmaceutical Sciences, at the ZTH Zurich, Switzerland. After earning his MChem degree at the University of York he completed a D.Phil in computational and synthetic inorganic chemistry under the joint supervision of Prof. Jennifer C. Green and Prof. Jonathan R. Dilworth at the University of Oxford, Merton College in 2008. From 2008 – 2010 he was a Postdoctoral Research Fellow and Scholar in the laboratory of Chief Radiochemist.  Dr Jason S. Lewis, Radiochemistry Service, Department of Radiology, Memorial SloanKettering Cancer Center, New York, USA. He has coauthored over 35 peer reviewed articles and has received a number of prestigious awards, scholarships and grants including an Honorable Mention Award in International Union of Pure and Applied Chemists IUPAC Prize for Young Chemists 2009. He is also member of the Royal Society of Chemistry and serves as a reviewer for several prominent peer reviewed journals in the area of inorganic chemistry, radiochemistry and computational chemistry.

Design, synthesis and evaluation of novel radiopharmaceuticals for targeting imaging of disease; drug and biomarker development and validation for use in positron emission tomography (PET) imaging of cancer; radiolabeling of monoclonal antibodies; synthetic and computational inorganic chemistry; transition metal chemistry and radiochemistry.

Dr. Peter L. Elkin is a Professor of Medicine at the Mount Sinai School of Medicine. He is the Center Director of Biomedical Informatics and the Vice President of Mount Sinai hospital for Biomedical and Translational Informatics. He received his Batchelor of Science from Union College and his M.D. from New York Medical College. He did his Internal Medicine residency at the Lahey Clinic and his NIH/NLM sponsored fellowship in Medical Informatics at Harvard Medical School and the Massachusetts General Hospital. Dr. Elkin has been working in Biomedical Informatics since 1981 and has been actively researching health data representation since 1987. He is the primary author of the American National Standards Institute’s ANSI national standard on Quality Indicators for Controlled Health Vocabularies ASTM E2087, which has also been approved by ISO TC 215 as a Technical Specification TS17117. He has chaired the OASIS International Healthcare Continuum and served as a cochair of Health and Human Service’s HITSP Technical Committee on Population Health. Dr. Elkin served as the cochair of the AHIC Transition Planning Group. Dr. Elkin is a Master of the American College of Physicians and a Fellow of the American College of Medical Informatics. Dr. Elkin chairs the International Medical Informatics Associations Working Group on Human Factors Engineering for Health Informatics. He was awarded the Mayo Department of Medicine’s Laureate Award for 2005. Dr. Elkin is the index recipient of the Homer R. Warner award for outstanding contribution to the field of Medical Informatics.

My research interests are the application of computer science and mathematics to biology and health. I design, implement and apply modern Ontologies in support of the biological sciences. My laboratory has compiled a genomic data analysis pipeline and we have built accurate natural language processing services. These services have abstracted phenotypes from clinical records and reports, facts from the literature in support of marker discovery and assertional knowledge from text based databases.

Dr. Andrzej Kloczkowski did his MSc Chemistry Warsaw University Poland in 1974. He did his PhD in Physical Chemistry  from Institute of Physical Chemistry of the Polish Academy of Sciences Warsaw Poland 1980 and his DSc Habilitation Physical Chemistry Warsaw University Poland 2001. He received his Postdoctoral Fellow from Stanford University in 1981 & 1983.
At present he is an Adjunct Professor of Iowa State University.

My research interests focus on various aspects of computational molecular biology and structural bioinformatics, Lattice models of proteins, Prediction of protein structures, Protein dynamics, Prediction of protein functions, Protein packing and statistical potentials, Prediction of binding sites, prediction of phosphorylation sites, Systems Biology.

Dr.  Steven Alan Enkemann was Director of Molecular Genomics Laboratory at H.Lee Moffitt Cancer Cernter

Molecular Genomics

Dr. Irina Burd is a perinatologist and a faculty member at the Department of Obstetrics and Gynecology at the University of Pennsylvania, USA. She earned her dual MD/PhD degrees at the University of Medicine of New Jersey Robert Wood Medical School. After that, she graduated from the residency in Obstetrics and Gynecology from Thomas Jefferson University, Philadelphia; and subsequently, from the Maternal Fetal Medicine fellowship at the University of Pennsylvania. She is a receipient of numerous awards, including the prestigious ABOG/AAOGF Award, Boggs Perinatology Award and Leon S. Israel Research Award. She serves as a reviewer of peerreviewed journals in the areas of Obstetrics and Gynecology, Perinatology and Fetal Neurodevelopment.

Obstetrics and Gynecology, Perinatology and Fetal Neurodevelopment.

Garry W. Buchko, Ph.D is Senior Research Scientist, Fundamental and Computational Sciences Directorate, Biological Sciences Division, Macromolecular Structure and Dynamics

Structural biology (proteins and/or DNA).Physical biochemistry.NMR spectroscopy.X-ray crystallography.DNA repair proteins and DNA lesions.Other spectroscopies - CD, EXAFS, IR.

Dr. Kobeissy is a Research Assistant Professor in the Department of Psychiatry, College of Medicine; University of Florida, Gainesville, FL. A native of Lebanon, Dr. Kobeissy graduated from the American University of Beirut with a Master’s degree in Immunology. He also holds a Master’s in Molecular Genetics from Bowling Green State University, Ohio. He obtained his PhD from the University of Florida in the area of Neuroscience, under the supervision of Dr. Kevin K Wang. He continued with the progress of his research as a Post-Doctorial Associate under the guidance of Drs. Mark S Gold and Kevin Wang. His current research overlaps the fields of neuroscience and psychiatry with a focus on drug abuse neurotoxicity and traumatic brain injury neuroproteomics. Dr. Kobeissy has authored more than 45 peer-reviewed scientific papers, ? reviews, and ? book chapters. He holds five patents in the areas of inflammation, drug abuse, and traumatic brain injury biomarkers. Dr. Kobeissy serves as an editorial member on several  journals related to proteomics and is a member of the VA RRD grant review panel. He is also an actively participating member at the Center of Neuroproteomics and Biomarker Research and at the Center for Traumatic Brain Injury Studies at theUniversity of Florida McKnight Brain Institute .

 

Neuroproteomics Analysis of Different Brain Injury Models
Analytical methodology development for protein separation and characterization.
Modeling Drug Abuse in Animal Models and In Cell culture (Acute vs. Chronic)
Secondhand smoke induced molecular effects on brain throughout neurological development and manifested behavioral/cognitive deficits and addiction.
Study of protein molecular dynamics associated with brain insults and drug abuse induced brain injury
Biochemical marker development of neurological injury and repair.
Systems Biology Analysis in Drug Abuse
 

Research in my laboratory is directed at developing novel gene therapy polymers as nucleic acid carriers and as antifungal agents. These polymers are comprised of histidines and lysines (HK) and can be varied in their degree of branching complexity.  For nucleic acid delivery, we have used HK peptides to deliver antiangiogenic “nucleic acids” (plasmids, siRNA, DNAzymes) for in vitro or in vivo model systems. Currently, my laboratory is examining the biophysical properties of the interactions of different polymers with nucleic acids and we are correlating these observations with the ability of polymers to transport nucleic acids intracellularly.  In addition to the nucleic acid experiments, present studies are ongoing to test the antifungal efficacy of HK peptides and their synergy with conventional antifungal drugs. Several biotech companies are actively developing these HK inventions as their lead product in areas of cancer therapeutics, wound healing, and antifungal treatments.

 
 

AdinCristian Andrei is an Assistant Professor, Biostatistics Department of Biostatistics Medical InformaticsUniversity of WisconsinMadison Highland Avenue, Madison WI, USA

My research interests lie in the areas of nonparametric and semiparametric survival analysis, recurrent/successive events, clinical trials, group sequential monitoring and quality-of-life.

Dr. Keqiang Ye is a tunured professor in Department of Pathology and Laboratory Medicine, Emory Univerisity, USA. He earned his Ph.D. at Emory University, Atlanta, GA. He has published more than 80 reviewed papers. He has been teaching experience of approximately 10 years. He served as a member of American Association for Cancer Research and Neuroscience Society. He served as a reviewer of peer reviewed journals in the area of neuroscicence, cell biology and lipidomics. He received many awards like ACS research scholar and Sontag Distinuished scientist middots award.

PI 3-kinase and phosphoinositol lipid signalings in the nucleus in cell survival in cancers and neurons; Drug development for Receptor Tyrosine kinases incluing Trk, IR and EGFR.

Dr. Pengyu Hong is a faculty member in Department of Computer Science, Brandeis University, USA. He earned his Ph.D. at University of Illinois at UrbanaChampaign. He has published more than 40 peer reviewed papers, and he was author of three book chapters. He has been teaching for more than 5 years. He served as a reviewer of peerreviewed journals in the area of cell biology, bioinformatics and computational biology, pattern recognition, computer vision, image processing, and statistics in medicine.

Mass spectrometry data analysis, high-content screening for drug discovery and functional genomics, biological network reconstruction.

Dr. Hailei Zhang completed her Bachelors of Mechanical Engineering, Dalian University of Technology, China, her Masters of Mechanical Engineering, Dalian University of Technology, China and her PhD, Computational Science and Pharmacy, National University of Singapore

1. Analyze large scale genomic data and integrate microarray data from different platforms to generate potential cancer targets for further screening 2. Investigation of potential cancer therapeutic targets through inverse docking and bioinformatics approach; 3. Prediction of disease-related proteins and miRNAs by statistical learning methods; 4. Development of parallel genetic algorithm and pseudo-excitation method for the large scale structural dynamic optimization; 5. Development of finite element method and algorithm for quantum mechanics.

Dr. Yang is currently an Associate Professor at Stevens Institute of Technology Mechanical Engineering Department and Director of MultiUser Micro Device Laboratory MDL. He received his B.S., M.S., Ph.D. degrees at Ajou University, Korea. In 1996, he joined Fujita MEMS research group at Institute of Industrial Science, University of Tokyo, Japan, as a Postdoctoral Scholar. Dr. Yang received a research fellowship from the Japan Society for the Promotion of Science from 1996 to 1998.

A-Wafer Transfer Temnology for MEMS Adaptive Optics

Dr. Manshui Zhou did his Ph.D. in Analytical Chemistry from the University of Illinois at Chicago his M.Sc. Analytical Chemistry in East China Normal University, China and his B.Sc. in Chemistry at East China Normal University, China

1.HPLC-QTRAP (ABSciex), UPLC-Quattro Premier XE (Waters), UPLC-SYNAPT G2 HDMS (Waters), QTOF(Bruker), TOF (JEOL), MALDI MS, DART-TOF MS. 2. Data Mining using mzMine and MATLAB

After receiving a Ph.D. degree from Philadelphia College of Pharmacy and
Sciences in 1997, Dr. Rong Shao, a postdoctoral fellow, participated in liver disease and
breast cancer research at Duke University Medical Center. During that professional
training period, Dr. Shao received a fellowship award from a federal funding agency the
Department of Defense (DoD) for a project focusing on breast cancer angiogenesis, and
also published a number of prestigious articles as the first author. In 2004, Dr. Shao was
recruited as a scientist and assistant professor at Pioneer Valley Sciences Institute,
University of Massachusetts Amherst, MA, where he continuously pursues the
mechanistic studies on tumor angiogenesis and metastasis. Since then, Dr. Shao has
published more than 20 papers in peer-reviewed journals, demonstrating that he is a
cancer biologist. He has also served as an editorial board member of three peer-reviewed
journals and a reviewer of more than ten journals. Dr. Shao’s research work has been
supported by a number of federal funding agencies including NIH (NCI) and DoD.
 

Our lab is primarily interested in identification of
angiogenic molecules and their mechanisms underlying tumor growth, vessel formation,
and metastasis. Tumor angiogenesis, the new vasculature formation from pre-existing
blood vessels, is a fundamental process required for tumor growth, and is initially
triggered by angiogenic factors that are mainly derived from tumor cells and tumorassociated
stroma cells, such as growth factors VEGF and bFGF. Those angiogenic
molecules specifically bind to membrane tyrosine kinase receptors to induce intracellular
angiogenic signaling cascades in endothelial cells, a major component of the blood
vasculature. We recently have discovered that a secreted glycoprotein referred to as
YKL-40 has the ability to promote tumor vascular endothelial cell angiogenesis; thus
promoting tumor progression and metastasis. Serum levels of YKL-40 were significantly
elevated in a broad spectrum of human cancers, including breast, colorectal, and ovarian
cancer, suggesting that YKL-40 may serve as a biomarker for the cancer diagnosis and
prognosis. We also established a monoclonal neutralizing anti-YKL-40 antibody that can
block tumor development and angiogenesis, which implicates therapeutic means for
inhibition of advanced cancers. In addition, our lab recently is also interested in the
pathogenesis of glioblastoma, an extremely aggressive brain tumor with a medium
survival of less than 15 months, irrespective of surgical resection and post-operative
adjuvant radio/chemotherapy. Glioblastoma is characterized by strong vascular
proliferation. We found that elevated YKL-40 is associated with angiogenesis and
malignancy of glioblastoma. Collectively, identification of the pathologic activities and
molecular mechanisms of YKL-40 elevated in human cancers may offer considerable
value for the diagnosis, prognosis, and therapy of cancer patients.
 

Hiroyuki Kobori is an Associate Professor of Physiology and of Medicine at Tulane University Health Sciences Center, USA. He received his MD degree 1990 and PhD degree 1998 from Keio University School of Medicine in Japan. After completing his residency and fellowships in internal medicine and nephrology in Keio University, he joined Tulane University as a postdoctoral research fellow in 1998. He subsequently became Instructor 2001, Assistant Professor 2003, and Associate Professor 2006. He has been also appointed as the Director of the Molecular Core in Tulane Hypertension and Renal Center of Excellence 2005. He is a recipient of distinguished awards including the Young Scholars Award of the American Society of Hypertension, Kidney Council New Investigator Award of the American Heart Association, and a finalist of Harry Goldblatt New Investigator Award of the American Heart Association. He is currently a fellow of the Japanese Society of Internal Medicine, the Japanese Society of Nephrology, the Japanese Society of Hypertension, the American Heart Association, the American Society of Nephrology, and the American College of Physicians.

His research interest has been in  the role of intrarenal angiotensinogen in the development and in the progression of hypertension and kidney diseases and The potential of urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status. His laboratory is actively engaged in a variety of studies from cell studies and animal studies to clinical studies and epidemiological studies.

Linghui Li is the Researcher in Addiction Pharmacology Research Laboratory in California Pacific Medical Center Research Institute She earned her PhD in Pharmacology at National University of Singapore She has published many papers in high profile international journals in the filed of pharmacogenetic and pharmacokinetics She is an active member in American Society of Clinical Pharmacology and Therapeutics She also served as a reviewer of peerreviewed journals in the area of pharmacology

Pharmacogenomics approach to identify genetic marker which can predict individual risk of addiction; Exploration of biomarker as sensitive outcome measurement in addiction treatment drug development.

D.Sivanesan, Ph.D is an Asst. Professor of Oncology Drug Discovery Program InCharge Macromolecular Modeling Core Dept. of Oncology,E401, New Research Building,Lombardi Cancer Center NCI Comprehensive Cancer Center, Georgetown University, Washington DC.

Post Genomics, Comprehensive Cancer

Vineet Gupta, PhD is an Assistant Professor in Medicine in the Division of Nephrology and Hypertension, Department of Medicine at the Miller School of Medicine, University of Miami. He is also CoDirector of the Peggy and Harold Katz Family Kidney Drug Discovery Center. Dr. Gupta earned his Ph.D. in Chemistry in 1998 from University of Rochester, Rochester, NY. He is a member of the American Chemical Society and the American Society of Nephrology. Dr. Gupta has published >15 peerreviewed papers in highimpact journals. He is also an adhoc reviewer for many peerreviewed journals in the fields of Chemistry, Biology, Cell Biology, Genomics, Proteomics and Inflammatory Diseases.

Dr. Gupta is interested in the mechanism of integrin activation and in modulating it with small molecules for treating a number of inflammatory and auto-immune diseases. Specifically, Dr. Gupta is studying integrin CD11b/CD18 (a.k.a. Mac-1, *M*2) that is primarily expressed on leukocytes and is central to the biological function of these important immune cells.

Dr.  Shona Dalal is an associate of epidemiology at Harvard School of Public Health.

Epidemiology, Post Genomics

debowale Adeyemo, 19811987 University of Ibadan, Ibadan, Nigeria?? Medical degree MD: Bachelor of Medicine, Bachelor of Surgery MBBS?? Graduated with a distinction in Anatomy and the departmental prize inSurgery19891994 University College Hospital, Ibadan, Nigeria?? Residency training in Pediatrics and Genetics?? Completed residency with a Fellowship of the West African College ofPhysicians FWACP

S06-GM008016-32 Admixture Mapping for Hypertension in African AmericansAdebowale Adeyemo (PI), 09/01/06-08/31/10NIH/NIGMS (MBRS/SCORE Program)R01-DK072128 Fine mapping and positional cloning of diabetes genesCharles Rotimi (PI) , 06/01/06 – 06/30/10NIH/NIDDK079791/Z/06-NEWPORT The genetic basis of podoconiosis: a model for geneenvironmentinteractionsMelanie Newport & Gail Davey (PIs), 12/01/06-12/31/09The Wellcome Trust, UK

Joseph Yeboah is an MD & MS of Department of Internal Medicine/Cardiology, University of Virginia.

Atherosclerosis

Dr. Melissa B. Davis completed her Postdoctoral Fellowship Training Yale University School of Medicine and Doctor of Philosophy in Molecular Genetics University of Georgia, USA

Molecular biomedical research, Networking environments and genomics data analysis packages, Functional genomics research combined with exceptional community service and organizational management

José Segovia is Professor in the Department of Physiology, Biophysics and Neuroscience at the Centro de Investigación y de Estudios Avanzados Cinvestav in Mexico City. He received his Ph.D from Georgetown University, Washington, D.C. and was a postdoctoral investigator at the University of California, Los Angeles. He has published 57 reviewed papers, is author of 7 book chapters, and has 16 years of teaching experience. He has served as reviewer of peerreviewed journals in the areas of Neuroscience, Gene Therapy, Pharmacology and Cancer.

Experimental gene therapy approaches for the treatment of gliomas, and neurodegenerative disorders.

Statistical Methodology:
Case-Control Studies of Gene-Environment Interactions; Es-
Interests timation Based on Pseudo-likelihood; Fine Genotype Mapping; Genome-Wide Asso-
ciation Studies; Haplotype-based Analysis; Markov Chain Monte Carlo Algorithms;
Measurement Error Modeling; Pathway-based Analysis; Seemingly Unrelated Regres-
sion; Semiparametric Methods.

Applied Statistics:
Genetic and Nutrition Epidemiology; Biomedical Studies; To de-
velop tools to not only extract the richest information from epidemiological and medical
studies, but also utilize that information in complex statistical models to answer impor-
tant biological questions and guide public health interventions, evaluations, and policies.
 

Dr. Narayanan Narayanan has obtained his PhD from University of Madras, Chennai and postdoctoral training from Medical University of South Carolina, Charleston, SC. He is an Assistant Professor at New York University School of Medicine.  Dr. Narayanan is working for the last 12 years on various aspects of molecular carcinogenesis and cancer prevention research, such as, cancer biomarkers, cancer genomics, including microRNAs  and proteomics, and molecular bioinformatics in several cancers, prostate, colon, breast and lung.  He has an extensive history of investigating the anticancer mechanisms of anti-inflammatory drugs, such as celebrex, exisulind, and licofelone, and nutritional bioactive food components, which include omega-3 fatty acids (fish oil), plant-derived pholyphenols, such as curcumin (active component of turmeric) and resveratrol (abundant in grapes and grape products such as red wine) in preclinical models of prostate cancer and has great enthusiasm in clinical translational research approaches. His research activities are funded by NIH/NCI and private foundations. To his credential, Dr. Narayanan has more than 35 peer-reviewed publications, in addition to several abstracts, and book chapters and reviews.

Narayanan has great enthusiasm in   clinical translational research approaches and molecular carcinogenesis and cancer prevention research such as, cancer biomarkers, cancer genomics, including micro RNAs  and proteomics, and molecular bioinformatics in several cancers, prostate, colon, breast and lung.
His research activities are funded by NIH/NCI and private foundations. To his credential, Dr. Narayanan has more than 35 peer-reviewed publications, in addition to several abstracts, and book chapters and reviews

 

I obtained my PhD from Imperial College, London in 2000, supervised by Professor Jeremy Nicholson.  Following this, I took the opportunity to move to the Netherlands where I worked as a post-doctoral research fellow for Unilever. Within this project, NMR spectroscopy, comprehensive chromatography methods and mass spectrometry were combined with advanced chemometric methodologies for analyzing biological samples, in order to study the correlationbetween metabolic responses of consumers and health effects of Functional Food ingredients.I later moved to the Netherlands largest contract research organization, TNO Food and Nutrition where I was employed as Project Leader Metabolomics.
In September 2004, I was appointed as a Lecturer in the School of Pharmacy, University of Nottingham, where I have established NMR spectroscopy-based metabolomics research at the University.

 

My primary research objective is the development and implementation of metabolomic methodology with the majority of my research projects focusing on the application of metabolomics for clinical studies into disease biomarker discovery, study of subtle metabolic changes such as health benefits of nutraceuticals, functional foods and dietary supplements and study of metabolite interactions and dynamics.

After obtaining her Pharmacy degree from the University of Kiel Germany 2005 Friederike Teichert received a scholarship for a PhD degree from the University of Leicester UK Her studies focussed on biomarker discovery for prostate carcinogenesis in a transgenic mouse model and chemopreventive efficacy of green tea polyphenols After completion of her doctorate degree she continued her work as a Research Associate in the Cancer Biomarkers and Prevention Group at the University of Leicester Her research is focussed on biomarker discovery and evaluation for cancer chemoprevention and cancer diagnostic clinical pilot studies Dr Teichert has published several papers in peerreviewed journals and received grant funding for short term studentships Furthermore she is involved in teaching activities and the implementation of Good Clinical Laboratory Practice in the laboratory

Metabolic profiling by NMR and LC-MS for biomarker discovery in cancer diagnosis and cancer chemoprevention. Method development for quantification of small molecules by LC-MS. Clinical and pre-clinical evaluation of cancer chemopreventive agents.

Hakima Amri holds a Ph.D. in Biochemistry and MS in Reproductive Physiology from Pierre and Marie Curie University, Paris, France. After completing her post-doctoral training in Molecular Endocrinology at the department of Cell Biology, she joined the department of Biochemistry and Cellular and Molecular Biology at Georgetown University to research natural therapeutics for cancer. Dr. Amri’s background and work in cancer research led to the creative application of phylogenetics to mutation-based diseases, such as cancer. This multi-disciplinary background provides her with a profound understanding of the disease biochemical pathways and the limitations facing biomedical research.  Most recently, she has been advocating the application of phylogenetics analysis to high-throughput omics. She shows that parsimony phylogenetics is a multidimensional dynamic analytical tool that is useful for disease modeling, profiling, and subtyping as well as biomarker discovery. Furthermore, it unravels clonal from non-expanded mutations and fathoms the primary origin of some cancers.

Biomarkers Discovery
Cancer bioinformatics
Natural cancer therapeutics
Integrative medicine

 

Dr Domenici is currently Translational Medicine Leader within the Neuroscience Center of Excellence of Drug Discovery GSK Verona where he has the responsibility of identifying and developing targets and biomarkers for mood disorders He has graduated in Biological Sciences Pisa in 1984 and received a PhD in Biological Chemistry at the Scuola Normale Superiore in 1990 After a short period as fellow at the St Jude Children Research Hospital and at the Mario Negri Institute for Pharmaceutical Research Milan in 1990 he joined Glaxo now GSK where he has gained about 20 years of experience in Drug Discovery in different therapeutic areas ranging from the identification of novel targets to the development of highthroughput screen programmes Since 2000 he has increased focus on the identification and validation of molecular biomarkers in neuroscience by a combination of genetic genomic and proteomic approaches He served as member of the Neuroscience Steering Committee at The Biomarker Consortium of the fNIH He is author of 40 scientific publications in peer reviewed journals and six book chapters He serves as reviewer of peerreview journals in the area of neuroscience and proteomics

Protein and gene expression biomarkers in neuroscience; molecular mechanisms underlying psychiatric disorders; mode of action of psychotropic drugs at genomic level; genome-wide approaches for the identification of novel biomarkers and targets for therapeutic intervention. Main expertise: proteomics, gene expression, pharmacogenetics.

She is worked as Director Institute of Clinical ChemistryUniversity Medical Center Research BuildingMartinistrasseHamburg Germany

Eppendorf Diagnostics

Dr.  Volker Daniel is an associate of Department of transplantation in university of Hiedelberg

Transplantion Emmunology

Genetic Profile of Hereditary Non Polyposis Colorectal Cancer
Handling life at high risk of Colorectal Cancer
Identification of Patients at-Risk for Hereditary Non-Polyposis Colorectal Cancer in Peruvian Hospital
Establishment of the Pathogenicity of UV in MLH1, MSH2 and MSH6genes in HNPCC
Whole Genome Approach of Basal Like Breast Cancer
Frequency of polymorphisms and protein expression ofcyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors
Genetic Couselling in Genetic’s Department of Public Hospital
Cytogenetic banding in Hereditary Syndromes
Genetic Breeding of Peruvian wild Tomatos
Hereditary Predisposition of Colorectal and Breast Cancer : Management of Patients and families with high risk, Molecular and Clinical Diagnostic, Genetic Couselling and  development of a system of registration and data management of oncogenetics data.
 

He completed his education The George Washington University Tsinghua University Tsinghua University

Rheumatology and Inflammation

Fumio Tsuji is the Senior Researcher in Research and Development Center Santen Pharmaceutical Co Ltd Japan He earned his PhD at Gifu University Japan He has published about 30 Reviewed papers He is one of the members in Japanese Pharmacological Society Japanese Society for Immunology Japanese Cancer Association American Chemical Society and American Association for the Advancement of Science He served as a reviewer of peerreviewed journals in the area of Immunopharmacology He is one of the Editorial board members in Research Reviews in Biosciences

Research and development of anti-inflammatory and anti-arthritic drugs using in vitro and in vivo techniques.

Dr.  Uehara is a researcher in the Department of Drug Safety Evaluation Shionogi Co Ltd and he is the head of toxicogenomics team in this company He earned his DVM and PhD from Tokyo University of Agriculture and Technology and Osaka Prefecture University respectively In addition he is one of the members of Japanese Toxicogenomics Informatics Project Until now he has published several scientific and review papers concerning toxicogenomics and biomarker research

Toxicogenomic approach to drug-induced toxicity; Biomarker research and development to improve the early detection, monitoring, and prognosis of toxicity.

Dr. Satomi Onoue is the associate professor in Department of Pharmacokinetics and Pharmacodynamics School of Pharmaceutical Sciences University of Shizuoka Japan He earned his PhD at University of Shizuoka Shizuoka Japan He has published 80 Reviewed papers and he was author of 2 book chapters He worked at Pfizer global research and development and he got 23 patents on new drug candidates DDS and research tools.

Development of peptide-based drug candidates for treatment of asthma/COPD, dry eye, and diabetes
Design of dry powder inhalation system for pulmonary administration of peptides
Development of novel analytical tools for predicting drug-induced phototoxicity of pharmaceutical substances

Kaname Ohyama is the assistant Professor in Department of Environmental and Pharmaceutical Sciences Nagasaki University Japan He earned his PhD at Nagasaki University He has published 30 reviewed papers and he was author of 3 book chapters He served as a reviewer of peerreviewed journals in the area of analytical chemistry pharmaceutical analysis and proteomics

Dr. Ohyama’s research interests lie in the area of toxicoproteomics, mainly focuses on protein changes in cells or tissues with exposure to toxicants, and separation science. Specifically, his group utilizes the novel proteomic approach, which is easily reproducible and highly sensitive, to study the mechanism of side-effects of pharmaceuticals including anticancer drugs.

Toru Suzuki is Associate Professor in the Graduate School of Medicine of the
University of Tokyo, Tokyo, Japan. He is a graduate of the Medical school of
the University of Tokyo. Research interests include proteomic and
epigenetic regulation of cardiovascular pathologies for focus on basic
science, biomarker development and proteomic technologies for translational
medicine, and cardiovascular disease with a particular interest on vascular
and aortic disease at the clinical end of the spectrum.
 

Research interests include proteomic and epigenetic regulation of cardiovascular pathologies for focus on basic
science, biomarker development and proteomic technologies for translational
medicine, and cardiovascular disease with a particular interest on vascular
and aortic disease at the clinical end of the spectrum.

Dr. Bin Zhou is the researcher in Translational Research Informatics Center Kobe Japan after she earned her PhD at Kyoto University She has published more than 20 Reviewed papers She was one of the members in Japanese society of clinical pharmacology She served as a reviewer of peerreviewed journals in the area of clinical research neurology and Alzheimer’s disease Dr Zhou is also one of the editorial members in Journal of Alzheimer’s disease

Clinical research and clinical trial design methods. Biomarkers for the clinical trial design in Neurological diseases. Development of novel diagnostic and therapeutics to treat Alzheimer’s disease.

Monika Podhorecka is a medical doctor she graduated from Medical University of Lublin Poland in 1998 She earned her PhD at the Department of Immunology Medical University of Lublin Currently she is a professor assistant in the Department of Hematooncology and Bone Marrow Transplantation of the University She published 45 reviewed papers and she was an author of 3 book chapters She has a teaching experience of more than 10 years She was one of the members of Polish Society of Hematology She served as a reviewer of peerreviewed journals in the area of hematology and pharmacology She was a member of organizing committee of international conferences on “Chronic lymphoid and myeloid malignancies” that was held in Lublin every two years She received several scientific awards for instance Polish Health Ministry Award Award of the Rector of Medical University of Lublin

Biology and treatment of chronic lymphoid malignancies, especially chronic lymphocytic leukemia, Apoptosis in pathogenesis of CLL, drug-induced apoptosis in CLL, DNA damage, DNA damage response

Chad Bousman completed his education in University of California San Diego School of MedicineSan Diego State UniversityCalifornia State University and in University of WisconsinLa Crosse

Post genomics, Biomarker Development

Dr. Crispin R. Dass [(BAppSci (Hons), PhD)] has 17 years of cell and molecular biology research experience, mainly focusing on oncological R&D.  He completed his secondary education in California, before moving to Australia for his tertiary education.  His research is on systems at various levels – in silico, in vitro, in vivo, ADME/Tox, clinical, and also in biomedical education fostering passion in young scientists.  His forte lies in formulation of nanoparticulate drug delivery systems for new and old compounds for cancer therapy.  He has worked on projects for Johnson & Johnson, GlaxoSmithKline, Amgen, and Novartis.  His extensive experience is documented in his 120 papers to date, with publications in Nature Medicine, Journal of the National Cancer Institute, Biomaterials, Nucleic Acids Research, Cancer, and Journal of Controlled Release. He is currently on the editorial board of 4 other journals in his field, and has been invited to chair sessions and to give keynote lectures at national and international conferences.  Based currently in St Albans (Melbourne, Australia), he has research links within Australia and in Thailand, Fiji, USA, China, South Korea, Japan, Iran and India. 
 

Cancer R & D
Drug delivery systems
Nanotechnology
Cell biology
Molecular biology
Developmental biology
Gene therapy
Protein therapy
Biomining for safer therapeutics
Tissue regeneration



 

Dr.  Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Dr Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine.
 

research interests focus on the development of novel nanodevices or nanotechnology for medical applications for stem cell tracking and overcoming multidrug resistance (MDR) of cancer.
 

Dr William Chi-shing Cho is the principal investigator of oncoproteomics and microRNA projects at the Department of Clinical Oncology in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK) and a fellow member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 120 papers covering cancer biomarkers, proteomics and microRNAs. He is a renowned scientist and also as an international grant reviewer of the Science Foundation (Ireland), National Medical Research Council (Singapore), Hope Funds for Cancer Research (USA) and Academia Sinica Investigator Award (Taiwan).
 

cancer biomarkers, proteomics, microRNAs, nasopharyngeal carcinoma, non-small cell lung cancer.


 

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China.  He is also served as a principle investigator at the Hong Kong Cancer Institute.  He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer. He has authored or co-authored ~120 papers and has written a number of books or book chapters.  He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents.  He was educated in China and United Kingdom and has MB and PhD degrees.
 

Apoptosis in cancer (hepatocellular carcinoma, lung cancer and thyroid cancer)
 

Dr. Bo Liu got his Ph.D. degree in Bioinformatics & Biochemistry from School of Life Sciences of Sichuan University in June 2010. Hitherto, he has made some academic achievements for exploring molecular mechanisms of plant lectin-induced cancer cell apoptosis and autophagy. He reported for the first time that Polygonatum cyrtonema lectin (PCL) could simultaneously induce cancer cell apoptosis and autophagy. Based upon the aforementioned findings, he has published 19 scientific peer-review papers as the first author/corresponding author in several known journals such as Autophagy, IJBCB, Cancer Letters,BBA, Biochimie and ABB. Furthermore, as an editorial member, he has co-written three academic books in autophagy field. So far, he has been invited to be a peer reviewer for more than 20 academic journals such as Apoptosis, Cancer Letters, Genomics, ABB, Peptides, Cell proliferation, Process Biochemistry and etc. Now, he is studying PPI-network-based identification of novel apoptotic and autophagic pathways in cancer.

 

Anti-cancer mechanims of plant lectins in vitro and in vivo
Apoptotic signaling pathways in human cancers
Autophagic signaling pathways in human cancers
Bioinformatics-based anti-cancer drug design

 

LU Da-Yong, oc/professor; ad/1288 Shangda Rd, 95-202, Shanghai200444, PR China; ed/ph D Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2005, MS, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1986, BS, Shanghai Medical University (Now Fudan University affiliated),1982; Now School of Life Sciences, Shanghai University, Shanghai200444, PR China.  Undergo the studies of cancer pathology, biochemistry pharmacology and clinical therapeutics from 1982 and some hypotheses in AIDS and neural science in 2007.  More than 20 scientific articles have been published in international journals.


 

My research interest of genomic study is in 3 disciplines
Individualized cancer chemotherapy by drug sensitivity tests and biomarker-orientated monotherapy and chemotherapy.
Suicidal ideations of antidepressants, pharmacogenomics or genomics study of antidepressants in different patients and suicidal outcomes.
Eradicative treatments of AIDS. Genomics study of pathogenesis of HIV in patients—a proposed strategy for eradicating HIV threat in patients.


 

Sherifa Ahmed Hamed, Associate Professor of Neurology, Faculty of Medicine, Assiut University Hospital born in October 26th, 1966, Beni Sueif, Egypt, Phone : 002 088 2371820, Fax: 002 088 2333327 and 002 088 2332278, Email:hamed_sherifa@yahoo.com, Mail Address: Department of Neurology and Psychiatry, 4th floor, Room # 4, Faculty of Medicine, Assiut University Hospital, Assiut, Egypt 71516. Dr. Hamed worked as a postdoctoral fellow in USA for two years (in Research Center for Genetic Medicine, Children?s National Medical Center, Dept. Integrative Systems Biology, George Washington University School of Medicine and Health Sciences). Her M.D. thesis project entitled “DNA sequence analysis for Structure/Function and mutation studies of Duchenne/Becker Muscular dystrophies”. Dr. Hamed served as a reviewer for 35 medical journals and she has a least 70 international publications in the field of Neurology, Neurogenetics and Neuropsychopharmacology. She supervised many thesis works for master and doctorate degrees.
 

Sang Soo Hah is an Assistant Professor in the Department of Chemistry at Kyung Hee University South Korea He received his PhD in Bioorganic Chemistry from the College of Natural Sciences at Seoul National University and worked as a Postdoctoral Fellow at Columbia University USA and at Lawrence Livermore National Laboratory USA in order to extend his research experience to the areas of molecular biology and toxicology and of cancer etiology and pharmacology He also worked in industry as a Research Fellow His current research program is broadly based on organic and biological chemistry of functional molecules and materials mainly focusing on protein/peptide and nucleic acid chemistry toxicology mechanisms of carcinogenesis and cancer pharmacology with ultimate goals of Drugs and Biomarkers Development He has served as a reviewer of peerreviewed journals in the areas of chemistry cancer biology and toxicology

Biochemistry, bioanalytical chemistry, chemical biology, cancer biology (etiology and pharmacology), biological accelerator mass spectrometry, assay development, drug and carcinogen metabolism, protein-ligand interactions, post-translational modifications, drug and biomarker development, radiation-induced protein expression, biomolecule-facilitated nanosciences, mutagenesis.

Zahra Mojtahedi received her medical doctor from Mashhad University of Medical Sciences in 1998 and her PhD from Shiraz University of Medical Sciences in 2008.  From 2008 to present, she has been an academic faculty at the Institute for Cancer Research of Shiraz University of Medical Sciences where she is now an Assistant Professor and Head of Cancer Proteomics Lab. She has published more than 20 articles in peer-reviewed journal. The major focus of Dr Mojtahedi research and activities is finding new biomarkers for cancer diagnosis, monitoring or therapy.

Dr Mojtahedi’s research interests are focused on uncovering of cancer biomarkers. Her team is trying to find novel markers for breast cancer aggressiveness. They are also trying to investigate Rho-GDI alpha functions and activities in different types of breast cancer. Several ongoing projects on lung cancer are underway for finding molecular mechanisms of umbelliprenin compound in lung cancer.
 

Dr. Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Because pyrimidine biosynthesis is an essential step in the progression of secondary Pseudomonas infections, PyrR presents an attractive anti-pseudomonal drug target. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors in the transcriptional regulation of human myeloperoxidase, a leukocyte enzyme implicated as causative agent in atherosclerosis and Alzheimer’s disease. Dr. Kumar relocated back to Singapore to join the Faculty of Medicine, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer biology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects. From a commercialization perspective, he co-filed a patent on a new potent PPARγ ligand for treatment of diabetes and cancer. Dr. Kumar has also successfully set up a USA-Singapore collaboration agreement for another 16 new derivatives drugs - activators and inhibitors of PPARγ for treatment of diabetes and cancer, thence to a clinical trial here in Singapore. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.

 

My area of research focuses on exploring the role of nuclear receptors, such as PPARs, ERα, HNF4α, and DEAD-box RNA helicases in the prevention and treatment of cancer. In addition, we also discovered a novel role for an RNA helicase, DDX20 in cancer cells involving the molecular aspects of tumor cell invasion and metastasis. While the role of HNF4α in regulating glucose metabolism in the liver and pancreas is already known, we are exploring how renal HNF4α contributes to glucose homeostasis, lipid mobilization, and mitochondrial β-oxidation in cellular, animal models, and in various types of nephropathy. Incidentally, down-regulation of HNF4α is also reported to contribute to the progression of liver and kidney cancer. We are also exploring the mechanism(s) involved in the regulation of a few novel HNF4α targets and ways to re-induce its tumor suppressor activity.
 

Genome analysis
Drug design
Mutation analysis
Protein-protein interaction
Docking simulation
Molecular dynamics simulation
Bioinformatics and Structural Biology.